← Eichor
Condition: Alk Tki Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Alk Tki

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Phase 3 · 1 location(s) · Queen Mary Hospital, Hong Kong · NCT06643416A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05014464Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Phase 2 · 16 location(s) · Lantern Pharma Inc. · NCT05456256Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT03042221Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Phase 3 · 157 location(s) · Nuvalent Inc. · NCT06765109
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.